Top news of the week: 01.12.2020.
Biotechnology, Smallpox, Vice President of the United States, Names of large numbers, Pulmonology, Health care
Startups
Biogen bets $1.5B on Sage's once-failed depression drug https://t.co/JRJyMDxAEi https://t.co/wS6CwneA1o
OpenBiogen bets $1.5B on Sage's once-failed depression drug
Biogen is paying $1.5 billion upfront for a stake in Sage Therapeutics’ once-failed depression therapy zuranolone and an earlier-phase asset. The agreement gives Biogen rights to a drug ...
"This is one of the largest strategic collaborations in the brain health space."
$BIIB $SAGE
https://t.co/swbExCniAu
OpenBiogen stocks up on Sage's brain drugs in $3B deal
By teaming up with Sage, Biogen gets its hands on two drugs in mid- to late-stage testing for multiple types of depression and essential tremor.
What do biotech companies need to ensure #diversity in their leadership and boardrooms? We put together a checklist of considerations discussed at this year’s BioPharm America Digital.
https://t.co/6WzvjAG0bb
OpenDiversity in leadership and boards: a checklist for biotech companies
We review key considerations for biotech companies to ensure diverse representation in leadership and boards.
RT @AndrewE_Dunn: 🧵 for a Friday scoop:
Top vaccine scientists are pitching a plan to launch a new trial "as soon as possible" for top coronavirus vaccines, specifically seeing if they can prevent transmission of the virus, BI has learned. (1/6)
https://t.co/YBMQ71KjgA
OpenScientists are aiming to launch a nationwide trial as soon as possible to find out if the top coronavirus vaccines can stop the virus from spreading
We know the top vaccines can prevent people from getting sick with COVID-19. But we don't know whether they prevent people from spreading the virus.
The company starts out with $42 million from 5AM Ventures, Atlas Venture and Gimv that will push the program, KN-002, into the clinic next year https://t.co/gHj403i0gU
OpenKinaset Therapeutics debuts with $40M for pan-JAK asthma med
There is a host of treatments for people with asthma, from inhaled and oral corticosteroids to newer injected biologics. But these drugs don’t work for everyone, because different factors ...
U.S loans $1.1 billion to Ginkgo Bioworks for pandemic effort https://t.co/iJni9q4nK1 https://t.co/iRitYaEIdg
OpenU.S. loans $1.1 billion to Ginkgo Bioworks for pandemic effort
The U.S. government has agreed to loan privately-held biotechnology firm Ginkgo Bioworks $1.1 billion for COVID-19 testing and the production of raw materials for therapies that may help ...
More info released on the new venture-backed bio-manufacturing services company Resilience- they bought Canadian company Therapure Biopharma & another undisclosed company. Lab space in San Diego & pending deal for Boston lab space https://t.co/s8rvo6UBds. Story by @rick_mullin3
,
OpenPharmaceutical services firm Resilience debuts, with questions
New company pitches itself as a disruptive engineering services firm in biopharmaceutical manufacturing
Jim Wilson teaming w/ $REGN to test a gene therapy version of Covid antibody cocktail.
https://t.co/Rjza7ZWcf4
OpenPenn Medicine Collaborates with Regeneron to Investigate Delivery of COVID-19 Antibody Cocktail via Gene Therapy Platform
A new University of Pennsylvania (Penn) research collaboration with Regeneron Pharmaceuticals, Inc. will investigate whether Regeneron’s casirivimab and imdevimab investigational antibody ...